Biologics

Ten years ago, India’s bioeconomy barely registered at $10 billion—a modest figure reflecting limited biotechnology commercialization and fragmented industry support. Fast forward to 2024, and that figure has exploded to $165.7 billion, representing one of the fastest biotechnology sector expansions globally. Yet India isn’t stopping there. The government has set an audacious target: building a […]

India’s pharmaceutical industry has operated for decades under a cloud of regulatory uncertainty. Approval timelines were unpredictable, expert panel selections remained opaque, and companies often complained about inconsistent decisions that cost time and money. That era is ending. The Central Drugs Standard Control Organisation has unveiled India’s first comprehensive formal rules governing drug approval panels,

India’s pharmaceutical industry stands at a crossroads. For decades, the country has dominated global generic drug production, earning its reputation as the world’s pharmacy. Yet this comfortable position masks a critical vulnerability: the absence of a complete drug innovation ecosystem. While India supplies over 60% of global vaccines and churns out affordable medicines for millions,

Former US President Donald Trump’s announcement of a 100% tariff on branded and patented pharmaceutical drugs has rattled India’s pharmaceutical sector. Effective 1st October 2025, this policy takes direct aim at biologics and complex generics—two of the fastest-growing segments for Indian manufacturers. India supplies nearly half the world’s generic medicines and leads global vaccine production,